Stable, recombinant AequoScreen® cell line expressing aequorin and the Prolactin-releasing peptide (PrRP) receptor, human recombinant in CHO-K1 host cells.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Cell Line Terms and Conditions must be accepted before orders are placed. Additional agreement needed for commercial use.
PerkinElmer’s AequoScreen® double transfected cell lines are provided in two vials of frozen cells, each containing ∽2.5 x 106 cells. Detailed product information as well as recommended cell culture conditions and validation assay date are available for each cell line.
The AequoScreen technology is a generic GPCR technology that can be used with Gs, Gi, and Gq-coupled GPCRs and calcium coupled ion channels. Following receptor stimulation, increases in intracellular calcium enable measurement of the resulting flash luminescence signal.
PerkinElmer’s AequoScreen cell lines require accepted cell line Terms and Conditions prior to order processing. Additional agreement needed for commercial use. Contact us using the Request More Information button above for additional information regarding required documentation.
|Assay Target Class||GPCR|
|Assay Target Type||Cell line|
|Assay Validated||Binding, Calcium Luminescence, Calcium Fluorescence|
|G-Alpha Natural Receptor||Gq/G11|
|Product Brand Name||AequoScreen|
|Receptor Type||Prolactin Releasing Peptide|
|Second Messenger Release||Calcium flux|
|Shipping Condition||Dry Ice|
|Special Ordering Information||Requires accepted Terms and Conditions. Additional agreement needed for commercial use.|
|Unit Size||5 million cells|
PerkinElmer’s validated, ready-to-use AequoZen™or cAMPZen™ frozen, irradiated cells make it easier for you to perform functional testing of GPCRs. Just thaw and use! Reliable, convenient AequoZen cells for aequorin calcium testing or cAMPZen cells for cAMP testing let you get the testing done. So yo ...
G protein coupled receptors (GPCRs) have been considered as a highly “druggable” target for many years, with over 40% of marketed drugs acting to modulate their function. For many years, radiometric techniques have dominated GPCR screening. However in the last decade the development of functional as ...